# Noubar Afeyan

> Noubar Afeyan is a Series B investor at Indigo backing Biotechnology. See 31 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Indigo
- Location: Cambridge, United States
- Total investments: 31
- Last investment: Apr 2026
- Lead investor: 71%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/noubarafeyan
- X (Twitter): https://twitter.com/NoubarAfeyan
- Facebook: https://www.facebook.com/noubar.afeyan

Noubar Afeyan is a Series B investor at Indigo in Cambridge focused on Biotechnology and Health Care. Noubar Afeyan is the Co-Founder of Etiome. He previously worked at Montai Health as a Co-Founder and Board Member. Noubar Afeyan attended the Massachusetts Institute of Technology.

## Contacts

5 contacts available for Noubar Afeyan: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/noubar-afeyan?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 17 | 55% |
| Health Care | 10 | 32% |
| Medical | 9 | 29% |
| Therapeutics | 6 | 19% |
| Life Science | 4 | 13% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 9 | 29% |
| Series A | 7 | 23% |
| Series C | 6 | 19% |
| Funding Round | 3 | 10% |
| Venture - Series Unknown | 3 | 10% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Serif Bio­med­i­cines | Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies. | $50M | Venture - Series Unknown | Apr 21, 2026 |  |
| Extuitive | Extuitive AI agents develop multiple product and ad versions and select the most effective concepts based on market trends. | $20M | Seed | Sep 18, 2025 |  |
| Terrana Biosciences | Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions. |  |  | Jul 01, 2025 |  |
| Terrana Biosciences | Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions. | $50M | Series B | Jul 01, 2025 |  |
| Prologue Medicines | Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features. | $50M | Series A | May 07, 2024 |  |
| Quotient Therapeutics | Quotient Therapeutics engages in transformative medicines made possible with somatic genomics. | $50M |  | Nov 21, 2023 |  |
| Quotient Therapeutics | Quotient Therapeutics engages in transformative medicines made possible with somatic genomics. | $50M | Seed | Nov 21, 2023 |  |
| Alltrna | Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNAlanguage and deliver diverse programmable molecules with broad therapeutic potential. | $109M | Series B | Aug 09, 2023 |  |
| Empress Therapeutics | Empress Therapeutics is a biotechnology business in its early stages focused on drug development and new molecular insights into health and illness. The company's proprietary bio platform uses evolution, human molecular and genetic data, and artificial intelligence to identify advanced starting points in endogenous drug-like molecules,allowing clinicians to treat a wide range of serious unmet medical needs with small-molecule drug candidates. | $50M | Venture - Series Unknown | Jun 21, 2023 |  |
| Metaphore Biotechnologies | Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore isdedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect. | $50M |  | May 16, 2023 |  |

10 of 31 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 4 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 4 deals together
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 3 deals together
- [BlackRock](https://shizune.co/investors/profile/blackrock) — VC Fund, 3 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-investments) — VC Fund, 3 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 3 deals together

## About Indigo

VC Fund · Boston, United States

Indigo is an agricultural technology company that focuses on improving the sustainability and productivity of agriculture. The company focuses on the microbes that have evolved in conjunction with plants over billions of years to optimize their health and maximize their productivity. Indigo believes we are at the forefront of something that servesthe needs of both farmers and consumers. For farmers, the yield benefits will help improve grower profitability while increasing our capacity to feed a growing population. For consumers, Indigo can begin to make fundamental changes in how our food is grown; like being more efficient with water, and reducing the use of nitrogen fertilizer and pesticides over time.

5 contacts available at Indigo.

| Name | Title | Profile |
| --- | --- | --- |
| John Gehring | Board Member | — |
| Barry Knight | Senior Vice President of Commercial Operations, North America | — |
| Corbett Jorgenson | Senior Vice President | — |
| Dan Harburg | Vice President, Global Head of Carbon Product and Technology | — |
| Dario Maffei | Chief Business Officer | https://shizune.co/investors/profile/dario-maffei-f416 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Noubar Afeyan invest in?

Noubar Afeyan invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Noubar Afeyan?

Public channels for Noubar Afeyan include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Noubar Afeyan last invest?

The most recent investment recorded for Noubar Afeyan closed in Apr 2026. Shizune tracks 31 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co